DE69620786T2 - Verwendung von cholinesterase-inhibitoren für die herstellung eines medikaments zur behandlung von xerostomie - Google Patents

Verwendung von cholinesterase-inhibitoren für die herstellung eines medikaments zur behandlung von xerostomie

Info

Publication number
DE69620786T2
DE69620786T2 DE69620786T DE69620786T DE69620786T2 DE 69620786 T2 DE69620786 T2 DE 69620786T2 DE 69620786 T DE69620786 T DE 69620786T DE 69620786 T DE69620786 T DE 69620786T DE 69620786 T2 DE69620786 T2 DE 69620786T2
Authority
DE
Germany
Prior art keywords
xerostomy
medicine
treatment
production
cholinesterase inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69620786T
Other languages
English (en)
Other versions
DE69620786D1 (de
Inventor
Joergen Ekstroem
Herbert Helander
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Calabar Billdal Se AB
Original Assignee
Biora AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biora AB filed Critical Biora AB
Publication of DE69620786D1 publication Critical patent/DE69620786D1/de
Application granted granted Critical
Publication of DE69620786T2 publication Critical patent/DE69620786T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
DE69620786T 1995-11-29 1996-11-25 Verwendung von cholinesterase-inhibitoren für die herstellung eines medikaments zur behandlung von xerostomie Expired - Lifetime DE69620786T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9504267A SE9504267D0 (sv) 1995-11-29 1995-11-29 New therapeutic use
PCT/SE1996/001531 WO1997019685A1 (en) 1995-11-29 1996-11-25 The use of cholinesterase inhibitors in the treatment of xerostomia

Publications (2)

Publication Number Publication Date
DE69620786D1 DE69620786D1 (de) 2002-05-23
DE69620786T2 true DE69620786T2 (de) 2002-11-21

Family

ID=20400405

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69620786T Expired - Lifetime DE69620786T2 (de) 1995-11-29 1996-11-25 Verwendung von cholinesterase-inhibitoren für die herstellung eines medikaments zur behandlung von xerostomie

Country Status (14)

Country Link
US (1) US5962503A (de)
EP (1) EP0866699B1 (de)
JP (1) JP4113257B2 (de)
CN (2) CN101380320B (de)
AR (1) AR004330A1 (de)
AT (1) ATE216235T1 (de)
AU (1) AU718661B2 (de)
DE (1) DE69620786T2 (de)
DK (1) DK0866699T3 (de)
ES (1) ES2175153T3 (de)
PT (1) PT866699E (de)
SE (1) SE9504267D0 (de)
WO (1) WO1997019685A1 (de)
ZA (1) ZA969586B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1401481A1 (de) * 2001-06-14 2004-03-31 Novo Nordisk A/S Schleimhautreparatur mit tff-dimer-peptiden
JP2006070027A (ja) * 2004-08-06 2006-03-16 Dai Ichi Seiyaku Co Ltd 口腔粘膜投与剤
US20060263414A1 (en) * 2005-05-19 2006-11-23 Pauline Pan Confectionery products for the treatment of dry mouth
US20070077300A1 (en) * 2005-09-30 2007-04-05 Wynn David W Oral compositions containing a salivation inducing agent
US20090053309A1 (en) * 2007-08-24 2009-02-26 Axiomedic Ltd., Gibraltar Adhesive compositions for the treatment of xerostomia
US9161909B2 (en) * 2007-08-24 2015-10-20 Axiomedic Ltd. Adhesive compositions for the treatment of xerostomia
CN114010575A (zh) * 2021-10-22 2022-02-08 江苏谛奇医药科技有限公司 新斯的明及其衍生物的新制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187165A (en) * 1987-05-15 1993-02-16 Hoechst-Roussel Pharmaceuticals Inc. Memory enhancing and analgesic 1,2,3a,8,8a-hexahydro-3a,8(and 1,3a,8)-di(and tri)methylpyrrolo[2,3-b]indoles
SE9103752D0 (sv) * 1991-12-18 1991-12-18 Astra Ab New compounds
US5387614A (en) * 1993-07-27 1995-02-07 University Of Iowa Research Foundation Use of sigma receptor ligands as salivary gland stimulants

Also Published As

Publication number Publication date
DK0866699T3 (da) 2002-08-12
EP0866699A1 (de) 1998-09-30
AU718661B2 (en) 2000-04-20
ATE216235T1 (de) 2002-05-15
WO1997019685A1 (en) 1997-06-05
AU7716096A (en) 1997-06-19
CN1207679A (zh) 1999-02-10
EP0866699B1 (de) 2002-04-17
PT866699E (pt) 2002-08-30
US5962503A (en) 1999-10-05
ZA969586B (en) 1997-05-29
SE9504267D0 (sv) 1995-11-29
CN101380320B (zh) 2010-12-29
AR004330A1 (es) 1998-11-04
ES2175153T3 (es) 2002-11-16
DE69620786D1 (de) 2002-05-23
JP4113257B2 (ja) 2008-07-09
CN101380320A (zh) 2009-03-11
JP2000508618A (ja) 2000-07-11

Similar Documents

Publication Publication Date Title
DE59608738D1 (de) Verwendung von epinastin für die behandlung von schmerzen
ATE283264T1 (de) Zwischenprodukte zur herstellung von metallproteinasehemmern
DE69841421D1 (de) Die verwendung von einem steroidsaponin zur behandlung von demenz
DE69629184D1 (de) Verwendung von vitamin d2 oder vitamin d4-derivaten zur herstellung eines medikamentes zur behandlung des sekundären hyperparathyroidismus
DE69518784D1 (de) Verfahren zur Herstellung von sanftem Tissuepapier
DE69312631D1 (de) Material für die behandlung von tierexkrementen und verfahrung zu dessen herstellung
DE69532990D1 (de) Ein zusammengesetzter gegenstand für die behandlung von dermatologischen narben, ein verfahren zur herstellung des gegenstandes und dessen verwendung
DE69626539D1 (de) topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen
DE69518082T2 (de) Verfahren zur Herstellung von sehr reiner Akrylsäure
DE69614609D1 (de) Verfahren zur Herstellung eines Einkristalles
DE59608309D1 (de) Verfahren zur Herstellung von photopolymeren Tiefdruckplatten
DE59504792D1 (de) Verfahren zur Herstellung von Serienventilen
DE68924714T2 (de) Verwendung von essentiellen fettsäuren zur herstellung eines medikaments zur behandlung von ekzemen.
DE69637449D1 (de) Verwendung von alpha-hydroxysäuren zur herstellung eines arzneimittels für die behandlung von entzündungen
ATE246518T1 (de) Egr-1 zur herstellung eines medikamentes zur behandlung von wunden
DE69207696D1 (de) Einschritt-Verfahren zur Herstellung von Dirithromycin
ATE390130T1 (de) Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden
DE69614739T2 (de) Pflaster zur Behandlung von Pflanzen
DE69620786D1 (de) Verwendung von cholinesterase-inhibitoren für die herstellung eines medikaments zur behandlung von xerostomie
DE69512977D1 (de) Material für die Behandlung von Tierexkrementen und Verfahren zu dessen Herstellung
DE69609882D1 (de) Verfahren zur Herstellung von normalen und überbasischen Phenolaten
DE69515666T2 (de) VERWENDUNG VON GnRH-ANTAGONISTEN ZUR HERSTELLUNG EINES MEDIKAMENTS ZUR BEHANDLUNG GONADEN-STEROID ABHÄNGIGER ERKRANKUNGEN
ATE234613T1 (de) Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen
DE3483944D1 (de) Verwendung von selektiv peripheren dopamin-antagonisten zur herstellung eines arzneimittels zur topischen behandlung von okularer hypertension.
DE69412934D1 (de) Verbessertes Verfahren zur Behandlung eines katalytischen Reformierungsproduktes

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: CALABAR AB, BILLDAL, SE